Alpha Tau Medical (DRTSW) Cash from Financing Activities (2021 - 2022)

Alpha Tau Medical (DRTSW) posted Cash from Financing Activities of $14.8 million for Q2 2022, down 81.93% sequentially from $82.0 million in Q1 2022.

Alpha Tau Medical (DRTSW) Cash from Financing Activities (2021 - 2022) Analysis & Trends

Alpha Tau Medical has reported Cash from Financing Activities for 2 years, with the latest figure at $14.8 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Financing Activities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-426.70 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-1.22 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	14.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-6.05 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	36.24 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-16.65 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	27.18 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-273.15 Mn
10	Alpha Tau Medical	383.00 Mn	200.58 Mn	-	-

Download Data